Ann: Continued Use of ResAppDx at COVID-19 Respiratory Clinic, page-51

Agreed @Chuckybee

The IP gathered over the past 3 months and that which will be collected during the extended period will be invaluable.
Not just with respect to the resappdx-eu algorithm and the underlying cough signature catalogue, but also evidence of integration within the workflow of a real world clinical setting.

The recent experience should have provided Resapp IT, Product Development and Business Development staff with critical insight(s) into the systems integration requirements and physical processes being used to manage patient flow within clinical and emergency response settings.

For those not familiar with B2B IT systems integration, it is not uncommon for the vendor to be tasked with identifying and/or providing suggested solutions to barriers to integration within the purchasers IT system(s) and physical processes, in order to get things across the line. It can be a slow process to join the dots, test and release and train. This IP goes straight into Resapp integration playbook for future reference.

With this in mind, Morayfield Clinic can have this at $0 for as long as they want (IMO), providing Resapp are yielding valuable IP, developing industry contacts and being provided with testimony (good, bad or indifferent) from Dr Evan Jones and his team.

Upon reflection, if we let the words "once in a 100 year global pandemic" sink in, we are actually dam lucky to have had this opportunity with the Morayfield Clinic. How many other established clinical settings would have let a new diagnostic tool anywhere near there current patient workflow....?

All IMO, but truth be told I still have NFI.